Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation: A secondary analysis based on two prospective studies.
Authors: Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Qin Xu
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.e17516
Source:
Full article
Abstract
e17516